New leadership within the FDA emphasized the importance of randomized controlled trials as of July 22, 2025.
1 report, 1 independent
Updated Jul 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
New leadership within the FDA emphasized the importance of randomized controlled trials as of July 22, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Vinay Prasad
US hematologist–oncologist
Nothing else this week.
Related events
- The FDA stated its intent to modernize regulatory processes to maintain leadership.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Nkarta is seeking protocol amendments for its clinical trials under the FDA.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Experimental therapies require approval from the FDA.
Coverage
Newest first; wire copies grouped- BloombergFDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink (Bloomberg) -- Replimune Group Inc. shares sank to their lowest point ever after US regulators rejected a skin cancer treatment from the bio